Global Information
회사소개 | 문의 | 비교리스트

세계의 영아연축 치료제 시장(2017-2021년)

Global Infantile Spasms Therapeutics Market 2017-2021

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 12월 상품 코드 421636
페이지 정보 영문 73 Pages
가격
US $ 2,500 ₩ 3,041,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,649,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,866,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,083,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 영아연축 치료제 시장(2017-2021년) Global Infantile Spasms Therapeutics Market 2017-2021
발행일 : 2016년 12월 페이지 정보 : 영문 73 Pages

영아연축은 유아 및 아동의 간질 증후군에서 볼 수 있는 발작의 일종으로 웨스트 증후군으로도 불리고 있습니다. 세계의 영아연축 치료제 시장은 2017-2021년 연평균 성장률(CAGR) 10.16%로 성장할 전망입니다.

세계의 영아연축 치료제(Infantile Spasms Therapeutics) 시장에 대해 조사했으며, 시장 동향과 과제, 제형별, 투여 경로별 및 지역별 동향, 2021년까지 시장 성장 전망, 주요 벤더 개요 등의 정보를 전해드립니다.

제1장 주요 요약

제2장 조사 범위

제3장 시장 조사 방법

제4장 서론

제5장 영아연축 : 개요

제6장 시장 상황

  • 시장 개요
  • Five Forces 분석

제7장 제형별 시장 세분화

  • 고형
  • 액체

제8장 투여 경로별 시장 세분화

  • 경구
  • 비경구

제9장 지역 세분화

  • 아메리카
  • 유럽, 중동 및 아프리카
  • 아시아태평양 지역

제10장 시장 성장 촉진요인

  • 2017-2021년의 주요 약제 출시
  • 진단의 과학적 진보
  • 특정 규제 지정

제11장 성장 촉진요인의 영향

제12장 시장이 해결해야 할 과제

  • 발작 관리 기기의 사용 확대에 의한 투약 치료의 위협
  • 한정된 환자 인구
  • 적당한 파이프라인

제13장 성장 촉진요인과 해결해야 할 과제의 영향

제14장 시장 동향

제15장 벤더 구도

  • 경쟁 시나리오
  • 기타 주목해야 할 벤더

제16장 주요 벤더 분석

  • H. Lundbeck
  • Mallinckrodt Pharmaceuticals
  • INSYS Therapeutics

제17장 부록

제18장 Technavio 소개

도표

KSM 17.01.31

About Infantile Spasms Therapeutics

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox-Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Technavio's analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • H. Lundbeck
  • Mallinckrodt Pharmaceuticals
  • INSYS Therapeutics

Other Prominent Vendors

  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • ORPHELIA Pharma
  • Retrophin
  • Valerion Therapeutics

Market driver

  • Major drugs launch expected in 2017-2021
  • For a full, detailed list, view our report

Market challenge

  • Growing usage of seizure management devices, a threat to drug therapies
  • For a full, detailed list, view our report

Market trend

  • Development of devices and smartphone apps to detect seizures and track medications
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Infantile spasm: Overview

PART 06: Market landscape

  • Global infantile spasms therapeutics market
  • Five forces analysis

PART 07: Market segmentation by dosage form

  • Solid
  • Liquid

PART 08: Market segmentation by ROA

  • Oral
  • Parenteral

PART 09: Geographical segmentation

  • Infantile spasms therapeutics market in Americas
  • Infantile spasms therapeutics market in EMEA
  • Infantile spasms therapeutics market in APAC

PART 10: Market drivers

  • Major drugs launch expected in 2017-2021
  • Growing scientific advancements in diagnostics
  • Special regulatory designations

PART 11: Impact of drivers

PART 12: Market challenges

  • Growing usage of seizure management devices, a threat to drug therapies
  • Limited patient population
  • Moderate pipeline

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Development of devices and smartphone apps to detect seizures and track medications
  • Alternate drugs fill the gap
  • Reformulation of marketed drugs

PART 15: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 16: Key vendor analysis

  • H. Lundbeck
  • Mallinckrodt Pharmaceuticals
  • INSYS Therapeutics

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Snapshot of global infantile spasms therapeutics market 2016
  • Exhibit 03: Market overview of global infantile spasms therapeutics market
  • Exhibit 04: Opportunity analysis in developed and emerging markets
  • Exhibit 05: Global infantile spasm therapeutics market 2016-2021 ($ millions)
  • Exhibit 06: Approved infantile spasms therapeutics
  • Exhibit 07: Key customer segments of global infantile spasms therapeutics market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global infantile spasms therapeutics market by dosage form
  • Exhibit 10: Segmentation of global infantile spasms therapeutics market by ROA
  • Exhibit 11: Market share of global infantile spasms therapeutics market by ROA
  • Exhibit 12: Snapshot of global infantile spasms therapeutics market by geography
  • Exhibit 13: Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions)
  • Exhibit 14: Overview of infantile spasms therapeutics disease market in Americas
  • Exhibit 15: Market scenario in Americas
  • Exhibit 16: Healthcare system in US: Before and after reforms in ACA
  • Exhibit 17: Orphan drug development and regulatory challenges in America
  • Exhibit 18: Incentives provided for orphan drugs by US regulation
  • Exhibit 19: Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions)
  • Exhibit 20: Overview of infantile spasms therapeutics market in EMEA
  • Exhibit 21: Percentage share of epilepsy drugs market in EMEA by geography 2015
  • Exhibit 22: Market scenario in EMEA
  • Exhibit 23: Incentives provided for orphan drugs by EU regulation
  • Exhibit 24: Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 25: Overview of infantile spasms market in APAC
  • Exhibit 26: Market scenario in APAC
  • Exhibit 27: Incentives provided for orphan drugs by Japanese regulation
  • Exhibit 28: Incentives provided for orphan drugs by Australian regulation
  • Exhibit 29: Infantile spasms therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 30: CP-115 target indications
  • Exhibit 31: Clinical trial information for cannabidiol
  • Exhibit 32: Impact of drivers
  • Exhibit 33: Pipeline for infantile spasms therapeutics market
  • Exhibit 34: Pipeline molecules being developed for the treatment of infantile spasms disease
  • Exhibit 35: Impact of drivers and challenges
  • Exhibit 36: Impact of trends in global infantile spasms therapeutics market
  • Exhibit 37: Competitive structure analysis of global infantile spasm therapeutics market 2016
  • Exhibit 38: Geographical presence of key vendors
  • Exhibit 39: H. Lundbeck: Key highlights
  • Exhibit 40: H. Lundbeck: Strength assessment
  • Exhibit 41: H. Lundbeck: Strategy assessment
  • Exhibit 42: H. Lundbeck: Opportunity assessment
  • Exhibit 43: Mallinckrodt Pharmaceuticals: Profile
  • Exhibit 44: Mallinckrodt Pharmaceuticals: Strength assessment
  • Exhibit 45: Mallinckrodt Pharmaceuticals: Strategy assessment
  • Exhibit 46: Mallinckrodt Pharmaceuticals: Opportunity assessment
  • Exhibit 47: INSYS Therapeutics: Key highlights
  • Exhibit 48: INSYS Therapeutics: Strength assessment
  • Exhibit 49: INSYS Therapeutics: Strategy assessment
  • Exhibit 50: INSYS Therapeutics: Opportunity assessment
Back to Top
전화 문의
F A Q